Treatment |
Incidence of EAE |
Mean peak clinical score |
Suppression of EAE |
Incidence |
Score |
Female PLP-primed T cells |
6/6 |
3.83 |
|
|
PTIO-treated female PLP-primed T cells |
0/6 |
0.17 |
100% |
95% a |
Male PLP-primed T cells |
0/6 |
0.25 |
100% |
93% a |
DETA-NONOate-treated male PLP-primed T cells |
6/6 |
3.5 |
|
|
Splenocytes isolated from male and female PLP-TCR transgenic mice were reprimed
with PLP 139-151 in the presence or absence of 50 μM PTIO and 100 μM
DETA-NONOate. After 4 d, CD4+ T cells were purified and 5 × 106 PLP-specific T
cells were transferred to naïve female SJL/J mice via tail vein. Six recipient mice
(n=6) were used in each group. While a clinical score of 1 or more was considered
as the incidence of EAE in mice. ap < 0.001 vs female PLP-primed T cells. |
